Browse by Poster Presenter

Type here to filter the list

F
Fabbri, Raffaella

S. Orsola-Malpighi Hospital of Bologna
(P 06) GONADOTOXICITY RISK EVALUATION AND REPRODUCTIVE OUTCOMES IN YOUNG ADULTS WITH SOFT TISSUE AND BONE SARCOMA TREATED WITH CHEMOTHERAPY AND/OR RADIATION THERAPY: A SINGLE CENTER RETROSPECTIVE STUDY
Raffaella Fabbri
Favorite
Fabbroni, Chiara

Fondazione IRCCS Istituto Nazionale dei Tumori
(P 292) OUTCOMES IN PLEOMORPHIC LIPOSARCOMA OF THE EXTREMITY AND TRUNK: IS MULTIMODALITY THERAPY INDICATED?
Chiara Fabbroni
Favorite
Fagioli, Franca

Paediatric Onco-Haematology Division, Regina Margherita Children’s Hospital, City of Health and Science of Turin and Department of Public Health and Paediatrics, University of Turin
(P 029) MOLECULAR CHARACTERIZATION OF OSTEOSARCOMA AND EWING SARCOMA IN PEDIATRIC PATIENTS REVEALS NOVEL RNA-BASED INTERVENTION POINTS.
Franca Fagioli
Favorite
Fahs, Assil

Duke University School of Medicine
(P 254) THE IMPACT OF MST (HIPPO KINASE) INHIBITION ON CHROMATIN ACCESSIBILITY AND ONCOGENIC PHENOTYPES IN FUSION-POSITIVE RHABDOMYOSARCOMA
Assil Fahs
Favorite
Fairweather, Mark

Brigham and Women's Hospital/Harvard Medical School
(P 214) EXPERIENCE OF MANAGEMENT FOR LOCALIZED PARATESTICULAR LIPOSARCOMA: A SINGLE INSTITUTION COHORT
Mark Fairweather
Favorite
(P 218) PRIMARY PELVIC SOFT TISSUE SARCOMAS (PELVISARC): OUTCOMES IN A SERIES OF 401 PATIENTS FROM THE TRANSATLANTIC AUSTRALASIAN RETROPERITONEAL SARCOMA WORKING GROUP (TARPSWG)
Mark Fairweather
Favorite
Falcón González, Alejandro

Hospital Universitario Virgen del Rocío Sevilla and Instituto de BioMedicina de Sevilla
(P 102) EFFICACY AND SAFETY OF VIMSELTINIB IN TENOSYNOVIAL GIANT CELL TUMOUR: PHASE 2 EXPANSION
Alejandro Falcón González
Favorite
Falkenhorst, Johanna

Department of Medical Oncology, Sarcoma Center, West German Cancer Center, University Duisburg-Essen, Medical School, Essen, Germany
(P 108) NILOTINIB REVISITED: SALVAGE USE IN PATIENTS WITH SEVERE IMATINIB-TOXICITY
Johanna Falkenhorst
Favorite
(P 121) USING IN VITRO MODELS TO PREDICT IMATINIB RESPONSES IN PDGFRA-MUTANT GASTROINTESTINAL STROMAL TUMOR
Johanna Falkenhorst
Favorite
(P 176) FIBROBLAST ACTIVATION PROTEIN ALPHA AS THERANOSTIC TARGET IN SARCOMA
Johanna Falkenhorst
Favorite
Farma, Jeffrey

Fox Chase Cancer Center
(P 220) PROMOTING GLOBAL EDUCATION IN THE FIELD OF RETROPERITONEAL SARCOMA: THE FIRST OPEN-ACCESS EDUCATIONAL WEBINAR SERIES BY THE TRANSATLANTIC AUSTRALASIAN RETROPERITONEAL SARCOMA WORKING GROUP
Jeffrey Farma
Favorite
(P 221) SURGICAL OUTCOMES OF NEOADJUVANT THERAPY FOR GASTROINTESTINAL STROMAL TUMORS: A SINGLE INSTITUTION ANALYSIS
Jeffrey Farma
Favorite
Faron, Matthieu

Department of Surgical Oncology, Institut Gustave Roussy
(P 217) PLANNED MARGINAL (R1) RESECTION IN PRIMARY RETROPERITONEAL SARCOMAS: RETROSPECTIVE SERIES ON 168 PATIENTS FROM A NATIONAL SPECIALIZED REFERRAL CENTER
Matthieu Faron
Favorite
(P 218) PRIMARY PELVIC SOFT TISSUE SARCOMAS (PELVISARC): OUTCOMES IN A SERIES OF 401 PATIENTS FROM THE TRANSATLANTIC AUSTRALASIAN RETROPERITONEAL SARCOMA WORKING GROUP (TARPSWG)
Matthieu Faron
Favorite
Farzaliyev, Farhad

Department of Plastic Surgery, BG Klinik Tübingen, Tübingen, Germany
(P 108) NILOTINIB REVISITED: SALVAGE USE IN PATIENTS WITH SEVERE IMATINIB-TOXICITY
Farhad Farzaliyev
Favorite
Fauske, Lena

Oslo University Hospital
(P 115) PSYCHOLOGICAL AND SOCIAL CHALLENGES OF PATIENTS WITH ADVANCED AND METASTATIC GASTROINTESTINAL STROMAL TUMORS ON LONG-TERM TREATMENT WITH TYROSINE KINASE INHIBITORS: A QUALITATIVE STUDY
Lena Fauske
Favorite
Fausti, Valentina

Clinical and Experimental Oncology, Immunotherapy, Rare Cancers and Biological Resource Center, IRCCS Istituto Romagnolo Per Lo Studio Dei Tumori (IRST) "Dino Amadori", Meldola, Italy.
(P 195) THE STRATEGIC ROLE OF 3D CULTURE SYSTEMS AND ZEBRAFISH NEAR-PATIENTS PRECLINICAL PLATFORMS AS PREDICTIVE TOOLS OF CHEMOTHERAPY RESPONSE FOR SARCOMA
Valentina Fausti
Favorite
(P 250) SYSTEMIC INFLAMMATORY INDICES IN SECOND LINE SOFT TISSUE SARCOMAS PATIENTS: FOCUS ON LYMPHOCYTE/MONOCYTE RATIO AND TRABECTEDIN ACTIVITY
Valentina Fausti
Favorite
Fazio, Roberta

Medical Oncology and Hematology Unit, Humanitas Clinical and Research Center, IRCCS, Rozzano, 20089, Italy
(P 08) HOW TO DEVELOP AN ADOLESCENT AND YOUNG PROGRAM IN AN ADULT CANCER CENTER: THE HUMANITAS RESEARCH HOSPITAL EXPERIENCE
Roberta Fazio
Favorite
(P 117) SHOULD REGORAFENIB BE PRESCRIBED AS A CONTINUOUS SCHEDULE AT LEAST IN GASTROINTESTINAL STROMAL TUMORS (GIST)?
Roberta Fazio
Favorite
Federman, Noah

David Geffen School of Medicine, UCLA Jonsson Comprehensive Cancer Center
(P 015) A SIGNAL FINDING STUDY OF NIVOLUMAB AND RELATLIMAB IN ADVANCED CHORDOMA
Noah Federman
Favorite
(P 039) THE GENOMIC AND IMMUNE LANDSCAPE OF OSTEOSARCOMA
Noah Federman
Favorite
(P 144) A PHASE 1/2 DOSE ESCALATION/EXPANSION STUDY OF ZN-C3 PLUS GEMCITABINE IN RELAPSED/REFRACTORY OSTEOSARCOMA
Noah Federman
Favorite
(P 183) OSTEOSARCOMA ORGANOIDS RECAPITULATE TUMOR CHARACTERISTICS AND MAINTAIN HETEROGENEITY
Noah Federman
Favorite
(P 184) PAN-SARCOMA ORGANOID SCREENING PIPELINE
Noah Federman
Favorite
(P 193) TARGETING THE PAX-FOXO FUSION VIA HDAC INHIBITION IN RHABDOMYOSARCOMA
Noah Federman
Favorite
(P 313) A PHASE 2, MULTICENTER, OPEN-LABEL BASKET TRIAL OF NAB-SIROLIMUS FOR PATIENTS WITH MALIGNANT SOLID TUMORS HARBORING PATHOGENIC INACTIVATING ALTERATIONS IN TSC1 OR TSC2 GENES (PRECISION I)
Noah Federman
Favorite
Feichtinger, Julia

Division of Cell Biology, Histology and Embryology, Gottfried Schatz Research Center, Medical University of Graz, Graz
(P 141) TUMOUR-INFILTRATING IMMUNE CELLS IN SOFT TISSUE SARCOMA. IMPACT ON LOCAL RECURRENCE, DISTANT METASTASIS, AND OVERALL SURVIVAL.
Julia Feichtinger
Favorite
Fendler, Wolfgang

Department of Nuclear Medicine, West German Cancer Center, University Hospital Essen
(P 176) FIBROBLAST ACTIVATION PROTEIN ALPHA AS THERANOSTIC TARGET IN SARCOMA
Wolfgang Fendler
Favorite
Feng, Xiaolan

Cumming School of Medicine, University of Calgary, Tom Baker Cancer Center
(P 165) REAL- WORLD EXPERIENCE OF TYROSINE KINASE INHIBITORS IN PATIENTS WITH RECURRENT BONE TUMOURS (BT): A CANSARCC STUDY
Xiaolan Feng
Favorite
Feng, Yun

The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, 510080
(P 101) CYTOREDUCTIVE SURGERY FOR METASTATIC GASTROINTESTINAL STROMAL TUMORS TREATED WITH RIPRETINIB: A SINGLE-CENTER ANALYSIS.
Yun Feng
Favorite
Fenwick, Nicola

University of Birmingham
(P 148) ANALYSIS OF REECUR TRIAL DATA TO EVALUATE POTENTIAL PROGNOSTIC FACTORS IN RECURRENT AND PRIMARY REFRACTORY EWING SARCOMA (RR-ES)
Nicola Fenwick
Favorite
Ferdinandus, Justin

Department of Nuclear Medicine, West German Cancer Center, University Hospital Essen
(P 176) FIBROBLAST ACTIVATION PROTEIN ALPHA AS THERANOSTIC TARGET IN SARCOMA
Justin Ferdinandus
Favorite
Ferguson, Michael

Indiana University; Riley Hospital for Children
(P 192) TARGETING PI3K/MTOR MITIGATES RESISTANCE TO CDK4/6 INHIBITION IN RB-PROFICIENT PEDIATRIC AND AYA OSTEOSARCOMAS
Michael Ferguson
Favorite
(P 226) ASSESSING PREDICTIVE VALUE OF RNA-SEQ OF B4GALNT1 AND ST8SIA1 AS BIOMARKERS OF GD2 EXPRESSION IN PEDIATRIC SARCOMAS
Michael Ferguson
Favorite
Ferguson, Peter

Department of Surgery, Mount Sinai Hospital; Department of Surgery, University of Toronto; Department of Surgical Oncology, Princess Margaret Cancer Centre, University of Toronto; CanSaRCC, Princess Margaret Cancer Centre, Toronto
(P 059) SURGICAL MANAGEMENT OF CHONDROSARCOMA OF LONG BONES UTILIZING A PRE-OPERATIVE RADIOLOGIC AGGRESSIVENESS SCORE?
Peter Ferguson
Favorite
(P 068) CLINICO-DEMOGRAPHIC CHARACTERISTICS AND OUTCOMES OF RADIATION-INDUCED SARCOMAS: A CANADIAN SARCOMA RESEARCH AND CLINICAL COLLABORATION (CANSARCC) STUDY
Peter Ferguson
Favorite
(P 180) INVESTIGATING CLINICAL FACTORS ASSOCIATED WITH THE ESTABLISHMENT OF SUCCESSFUL PRIMARY HUMAN SOFT TISSUE SARCOMA CELL LINES
Peter Ferguson
Favorite
(P 284) HOW DO THE OUTCOMES OF RADIATION ASSOCIATED PELVIC AND SACRAL BONE SARCOMAS COMPARE TO PRIMARY OSTEOSARCOMAS FOLLOWING SURGICAL RESECTION?
Peter Ferguson
Favorite
(P 304) SURGICAL STAGING OF OSTEOSARCOMA: WHAT IS THE OPTIMAL METHOD FOR PREDICTING LOCAL RECURRENCE?
Peter Ferguson
Favorite
Ferlauto, Harrison

Icahn School of Medicine at Mount Sinai
(P 288) LOCKING PLATE AUGMENTATION OF POLYMETHYLMETHACRYLATE-FILLED DISTAL FEMUR DEFECTS
Harrison Ferlauto
Favorite
Fernández, Juan Angel

"La Arrixaca" University Hospital
(P 055) PROGNOSTIC VALUE AND USEFULNESS OF HAEMATOLOGICAL BIOMARKERS IN LIPOSARCOMAS.
Juan Angel Fernández
Favorite
(P 078) GASTROINTESTINAL STROMAL TUMOURS (GIST) AND RISK OF SECOND NEOPLASMS. INCIDENCE RATE ANALYSIS
Juan Angel Fernández
Favorite
(P 119) SURGICAL MANAGEMENT OF GASTROINTESTINAL STROMAL TUMOURS SARCOMATOSIS (GISTOSIS). A RETROSPECTIVE MULTI-INSTITUTIONAL STUDY
Juan Angel Fernández
Favorite
(P 219) PROGNOSTIC VALUE OF HEMATOLOGICAL MARKERS IN LEIOMYOSARCOMA
Juan Angel Fernández
Favorite
(P 281) CUTANEOUS SARCOMA: CASE SERIES DESCRIPTION AND ANALYSIS OF FACTORS RELATED TO AN UNFAVORABLE EVOLUTION
Juan Angel Fernández
Favorite
(P 318) NEOADJUVANT CHEMORADIOTHERAPY IN ADVANCED SOFT TISSUE SARCOMA. UPDATED NASAR STUDY
Juan Angel Fernández
Favorite
Fernandez, Maria

RTI Health Solutions
(P 260) BURDEN OF ILLNESS OF DESMOID TUMORS
Maria Fernandez
Favorite
Fernández-Pérez, Juan

“La Arrixaca” Clinical University Hospital
(P 055) PROGNOSTIC VALUE AND USEFULNESS OF HAEMATOLOGICAL BIOMARKERS IN LIPOSARCOMAS.
Juan Fernández-Pérez
Favorite
Fernandez, Yanelys

University of Miami
(P 263) COMPARATIVE EFFECTIVENESS OF SYSTEMIC TREATMENTS IN DESMOID TUMORS
Yanelys Fernandez
Favorite
Ferrari, Andrea

Fondazione IRCCS Istituto Nazionale dei Tumori
(P 01) ANTITUMOR ACTIVITY OF CYTOTOXIC AND TARGETED AGENTS IN A PATIENT-DERIVED XENOGRAFT (PDX) OF DESMOPLASTIC SMALL ROUND CELL TUMOR (DSRCT) HIGHLIGHTS THE IRINOTECAN-TRABECTEDIN COMBINATION
Andrea Ferrari
Favorite
(P 145) A RETROSPECTIVE CASE SERIES ANALYSIS OF 22 RHABDOMYOSARCOMA PATIENTS WITH SPINDLE-CELL/SCLEROSING MORPHOLOGY
Andrea Ferrari
Favorite
Ferrari, Cristina

Laboratory of Experimental Oncology, Rizzoli Orthopedic Institute IRCCS
(P 031) PAZOPANIB IN ADVANCED BONE SARCOMA: A RETROSPECTIVE ANALYSIS OF RIZZOLI ORTHOPEDIC INSTITUTE
Cristina Ferrari
Favorite
Ferrari, Stefano

Istituto Ortopedico Rizzoli
(P 148) ANALYSIS OF REECUR TRIAL DATA TO EVALUATE POTENTIAL PROGNOSTIC FACTORS IN RECURRENT AND PRIMARY REFRACTORY EWING SARCOMA (RR-ES)
Stefano Ferrari
Favorite
Ferreira, Al

University of Miami
(P 243) MUTATIONAL ANALYSIS OF PRIMARY AND ADVANCED CHORDOMA TISSUE USING NEXT-GENERATION SEQUENCING
Al Ferreira
Favorite
Ferreiro-Monteagudo, Reyes

Department of Medical Oncology, Ramón y Cajal University Hospital
(P 157) MOLECULAR SCREENING OF ADVANCED SARCOMAS THROUGH NEXT-GENERATION SEQUENCING IN A TERTIARY UNIVERSITY HOSPITAL
Reyes Ferreiro-Monteagudo
Favorite
Ferreras- Martinez, David

“La Arrixaca” Clinical University Hospital
(P 055) PROGNOSTIC VALUE AND USEFULNESS OF HAEMATOLOGICAL BIOMARKERS IN LIPOSARCOMAS.
David Ferreras- Martinez
Favorite
(P 078) GASTROINTESTINAL STROMAL TUMOURS (GIST) AND RISK OF SECOND NEOPLASMS. INCIDENCE RATE ANALYSIS
David Ferreras- Martinez
Favorite
Fiaschi, Nathalie

Regeneron Pharmaceuticals
(P 131) MUCIN 16 (CANCER ANTIGEN 125) EXPRESSION IN EPITHELIOID SARCOMA LEADS TO SINGLE-PATIENT STUDY WITH BISPECIFIC T-CELL ENGAGER UBAMATAMAB (MUCIN16-CD3): A BENCH-TO-BEDSIDE EXPERIENCE
Nathalie Fiaschi
Favorite
Fice, Michael

Rush University Medical Center
(P 081) MISSING DATA IN THE DEVELOPMENT AND EXTERNAL VALIDATION OF MACHINE LEARNING MODELS FOR SURVIVAL PREDICTION IN SARCOMA
Michael Fice
Favorite
(P 206) RADIOTHERAPY LEADS TO IMPROVED OVERALL SURVIVAL IN PATIENTS UNDERGOING RESECTION FOR UNDIFFERENTIATED PLEOMORPHIC SARCOMA
Michael Fice
Favorite
(P 227) ASSOCIATION BETWEEN NEUTROPHIL-LYMPHOCYTE RATIO, PLATELET-LYMPHOCYTE RATIO, AND SURVIVAL IN UNDIFFERENTIATED PLEOMORPHIC SARCOMA
Michael Fice
Favorite
(P 273) 3D-PRINTED PATIENT-SPECIFIC CUTTING GUIDES VERSUS FREEHAND RESECTION FOR INTERNAL HEMIPELVECTOMY: CLINICAL AND ONCOLOGIC OUTCOMES
Michael Fice
Favorite
(P 277) BEARING SELECTION IN PROXIMAL FEMORAL REPLACEMENT: A COMPARISON OF CLINICAL OUTCOMES
Michael Fice
Favorite
(P 287) INTERNAL HEMIPELVECTOMY: A SINGLE INSTITUTION'S LEARNING CURVE AND LONGITUDINAL EXPERIENCE
Michael Fice
Favorite
(P 295) PERIACETABULAR INTERNAL HEMIPELVECTOMY WITH AND WITHOUT SACRAL RESECTION: AN INSTITUTIONAL EXPERIENCE AND SYSTEMATIC REVIEW
Michael Fice
Favorite
(P 300) RECONSTRUCTION FOLLOWING SACROILIAC TUMOR RESECTION: A SYSTEMATIC REVIEW
Michael Fice
Favorite
Filipowicz, Paulina

Medical University of Warsaw
(P 168) SYSTEMIC INFLAMMATION INDEX (SII) AS INDEPENDENT PREDICTIVE FACTOR IN PATIENTS WITH L-SARCOMA TREATED WITH TRABECTEDIN - ANALYSIS OF REAL-WORLD EVIDENCE FROM A REFERENCE CENTER
Paulina Filipowicz
Favorite
Fing Chan, Godfrey Chi

The University of Hong Kong
(P 043) A MULTICENTER, OPEN-LABEL, RANDOMIZED, PHASE 2 STUDY OF LENVATINIB IN COMBINATION WITH IFOSFAMIDE AND ETOPOSIDE VERSUS IFOSFAMIDE AND ETOPOSIDE IN CHILDREN, ADOLESCENTS, AND YOUNG ADULTS WITH RELAPSED OR REFRACTORY OSTEOSARCOMA
Godfrey Chi Fing Chan
Favorite
Fiore, Marco

Fondazione IRCCS Istituto Nazionale dei Tumori
(P 01) ANTITUMOR ACTIVITY OF CYTOTOXIC AND TARGETED AGENTS IN A PATIENT-DERIVED XENOGRAFT (PDX) OF DESMOPLASTIC SMALL ROUND CELL TUMOR (DSRCT) HIGHLIGHTS THE IRINOTECAN-TRABECTEDIN COMBINATION
Marco Fiore
Favorite
(P 052) PATHOLOGICAL AND RADIOLOGICAL RESPONSE AFTER NEOADJUVANT TREATMENTS IN PRIMARY RESECTABLE MYXOFIBROSARCOMA AND UNDIFFERENTIATED PLEOMORPHIC SARCOMA OF THE EXTREMITIES AND TRUNK WALL
Marco Fiore
Favorite
(P 218) PRIMARY PELVIC SOFT TISSUE SARCOMAS (PELVISARC): OUTCOMES IN A SERIES OF 401 PATIENTS FROM THE TRANSATLANTIC AUSTRALASIAN RETROPERITONEAL SARCOMA WORKING GROUP (TARPSWG)
Marco Fiore
Favorite
(P 292) OUTCOMES IN PLEOMORPHIC LIPOSARCOMA OF THE EXTREMITY AND TRUNK: IS MULTIMODALITY THERAPY INDICATED?
Marco Fiore
Favorite
Flaman, Ashley

The Ottawa Hospital
(P 197) TUMOR IMMNUNE PROFILING AND IDENTIFICATION OF IMMUNOTHERAPEUTIC TARGETS IN DEDIFFERENTIATED LIPOSARCOMA
Ashley Flaman
Favorite
Flamant, Etienne

School of Medicine, Duke University
(P 171) CANINE-DERIVED OSTEOSARCOMA ORGANOIDS MODEL TUMOR HETEROGENEITY AND CHEMOTHERAPY RESISTANCE
Etienne Flamant
Favorite
Flanagan, Adrienne

University College London Cancer Institute
(P 011) TACKLE A RARE SARCOMA THROUGH A COLLABORATIVE APPROACH
Adrienne Flanagan
Favorite
(P 252) THE GENOMIC LANDSCAPE OF CLEAR CELL SARCOMA RESEARCH INITIATIVE
Adrienne Flanagan
Favorite
Flaus, Andrew

University College Galway
(P 235) ELUCIDATING THE ONCOGENIC EFFECT OF BCOR-ITD IN SARCOMA
Andrew Flaus
Favorite
Fletcher, Amanda

Duke
(P 034) REGIONAL ANESTHESIA IMPROVES METASTASIS FREE SURVIVAL AFTER SURGICAL RESECTION OF BONE SARCOMAS
Amanda Fletcher
Favorite
Fletcher, Benjamin

Department of Medical Oncology, Sarcoma Center, West German Cancer Center, University Duisburg-Essen, Medical School, Essen, Germany
(P 108) NILOTINIB REVISITED: SALVAGE USE IN PATIENTS WITH SEVERE IMATINIB-TOXICITY
Benjamin Fletcher
Favorite
Fletcher, Jonathan

Brigham and Women’s Hospital
(P 099) CONCURRENT INHIBITION OF CDK2 ADDS TO THE ANTI-TUMOR ACTIVITY OF CDK4/6 INHIBITION IN GIST
Jonathan Fletcher
Favorite
Flint, James

UC San DIego
(P 279) CEMENT AUGMENTATION WITH CEPHALLOMEDUALLARY FIXATION OF PRIMARY AND METASTATIC LESIONS OF THE PROXIMAL FEMUR.
James Flint
Favorite
Flint, James

Naval Medical Center San Diego; University of California San Diego
(P 282) FUNGATING SOFT TISSUE SARCOMA: A COMPLEX TREATMENT DILEMMA
James Flint
Favorite
Focaccia, Marco

University of Toronto
(P 059) SURGICAL MANAGEMENT OF CHONDROSARCOMA OF LONG BONES UTILIZING A PRE-OPERATIVE RADIOLOGIC AGGRESSIVENESS SCORE?
Marco Focaccia
Favorite
Focaccia, Marco

IRCCS Rizzoli Orthopedic Institute, Orthopedic Oncology Unit
(P 304) SURGICAL STAGING OF OSTEOSARCOMA: WHAT IS THE OPTIMAL METHOD FOR PREDICTING LOCAL RECURRENCE?
Marco Focaccia
Favorite
Foca, Flavia

Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori" - IRST IRCCS
(P 250) SYSTEMIC INFLAMMATORY INDICES IN SECOND LINE SOFT TISSUE SARCOMAS PATIENTS: FOCUS ON LYMPHOCYTE/MONOCYTE RATIO AND TRABECTEDIN ACTIVITY
Flavia Foca
Favorite
Foltz, Warren

University Health Network
(P 124) EFFECT OF MAGNETIC RESONANCE GUIDED HIGH INTENSITY FOCUSED ULTRASOUND AND CHEMOTHERAPY ON THE IMMUNE PROFILE OF A MURINE MODEL OF RHABDOMYOSARCOMA
Warren Foltz
Favorite
Fonio, Paolo

Radiology, University of Turin
(P 058) SARCOPENIA AS A NEGATIVE PROGNOSTIC FACTOR IN LOCALIZED EXTREMITIES/TRUNK WALL SOFT TISSUE SARCOMAS
Paolo Fonio
Favorite
Foote, Robert

Mayo Clinic (Rochester)
(P 289) MERKEL CELL CARCINOMA OF UNKNOWN PRIMARY: CLINICAL PRESENTATION AND OUTCOMES
Robert Foote
Favorite
Forrest, Suzanne

Dana-Farber / Boston Children's
(P 239) FGFR IS A RELEVANT MOLECULAR TARGET IN PEDIATRIC AND AYA SARCOMAS
Suzanne Forrest
Favorite
Fotiadis, Nicos

The Royal Marsden NHS Foundation Trust
(P 152) FINAL RESULTS OF GEMMK: A PHASE I TRIAL OF GEMCITABINE AND PEMBROLIZUMAB IN PATIENTS WITH LEIOMYOSARCOMA AND UNDIFFERENTIATED PLEOMORPHIC SARCOMA
Nicos Fotiadis
Favorite
Fox, Miranda

Inhibrx, Inc
(P 041) UPDATED EFFICACY AND SAFETY OF THE TETRAVALENT DEATH RECEPTOR 5 AGONIST INBRX-109 IN PATIENTS WITH CHONDROSARCOMA: DATA FROM THE PHASE 1 EXPANSION COHORTS
Miranda Fox
Favorite
(P 317) INBRX-109 IN EWING SARCOMA: PRECLINICAL RATIONALE FOR INITIATION OF A PHASE 1 CHEMOTHERAPY COMBINATION EXPANSION COHORT
Miranda Fox
Favorite
Fragoso Costa, Pedro

Department of Nuclear Medicine, West German Cancer Center, University Hospital Essen
(P 176) FIBROBLAST ACTIVATION PROTEIN ALPHA AS THERANOSTIC TARGET IN SARCOMA
Pedro Fragoso Costa
Favorite
Franceschini, Natasja

LUMC
(P 255) TRUNCATED FOS REDUCES OSTEOGENIC DIFFERENTIATION CAPACITY IN OSTEOID OSTEOMA AND OSTEOBLASTOMA
Natasja Franceschini
Favorite
Franchi, Alessandro

Section of Pathology, Department of Translational Research and of New Technologies in Medicine and Surgery, University of Pisa, Pisa, Italy
(P 016) ACTIVITY OF CHEMOTHERAPY IN MESENCHYMAL CHONDROSARCOMA: A MULTICENTRE RETROSPECTIVE ANALYSIS WITHIN THE ITALIAN SARCOMA GROUP
Alessandro Franchi
Favorite
Franz, Emily

Molecular, Cellular, and Developmental Biology Graduate Program, The Ohio State University; Center for Childhood Cancer, Nationwide Children’s Hospital
(P 140) TRABECTEDIN ENHANCES ONCOLYTIC HERPES SIMPLEX VIROIMMUNOTHERAPY BY REDUCING BARRIERS TO VIRUS SPREAD AND IMMUNE EFFECTOR FUNCTION IN PRECLINICAL BONE SARCOMA MODELS
Emily Franz
Favorite
Frassineti, Luca

Clinical and Experimental Oncology, Immunotherapy, Rare Cancers and Biological Resource Center, IRCCS Istituto Romagnolo Per Lo Studio Dei Tumori (IRST) "Dino Amadori", Meldola, Italy.
(P 195) THE STRATEGIC ROLE OF 3D CULTURE SYSTEMS AND ZEBRAFISH NEAR-PATIENTS PRECLINICAL PLATFORMS AS PREDICTIVE TOOLS OF CHEMOTHERAPY RESPONSE FOR SARCOMA
Luca Frassineti
Favorite
Freed, Daniel

Chordoma Foundation
(P 013) A PHASE 2 TRIAL OF CETUXIMAB FOR PATIENTS WITH LOCALLY ADVANCED/METASTATIC CHORDOMA
Daniel Freed
Favorite
Freeman, Carolyn

McGill University Health Centre
(P 092) THE SARCOMA-SPECIFIC QUALITY OF LIFE STUDY (SARC-QOL): IDENTIFYING KEY DOMAINS OF HEALTH-RELATED QUALITY OF LIFE IN ADULT PATIENTS WITH EXTREMITY SOFT TISSUE SARCOMA
Carolyn Freeman
Favorite
Frega, Giorgio

Osteoncology, Bone and Soft Tissue Sarcomas and Innovative Therapies Unit IRCCS Istituto Ortopedico Rizzoli, Bologna, Italy
(P 031) PAZOPANIB IN ADVANCED BONE SARCOMA: A RETROSPECTIVE ANALYSIS OF RIZZOLI ORTHOPEDIC INSTITUTE
Giorgio Frega
Favorite
(P 245) MUTATIONAL STATUS OF CHONDROSARCOMA BASED ON TARGETED NEXT-GENERATION SEQUENCING ANALYSIS
Giorgio Frega
Favorite
Frezza, Anna Maria

Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy
(P 01) ANTITUMOR ACTIVITY OF CYTOTOXIC AND TARGETED AGENTS IN A PATIENT-DERIVED XENOGRAFT (PDX) OF DESMOPLASTIC SMALL ROUND CELL TUMOR (DSRCT) HIGHLIGHTS THE IRINOTECAN-TRABECTEDIN COMBINATION
Anna Maria Frezza
Favorite
(P 016) ACTIVITY OF CHEMOTHERAPY IN MESENCHYMAL CHONDROSARCOMA: A MULTICENTRE RETROSPECTIVE ANALYSIS WITHIN THE ITALIAN SARCOMA GROUP
Anna Maria Frezza
Favorite
(P 052) PATHOLOGICAL AND RADIOLOGICAL RESPONSE AFTER NEOADJUVANT TREATMENTS IN PRIMARY RESECTABLE MYXOFIBROSARCOMA AND UNDIFFERENTIATED PLEOMORPHIC SARCOMA OF THE EXTREMITIES AND TRUNK WALL
Anna Maria Frezza
Favorite
(P 170) ANTITUMOR ACTIVITY OF TAZEMETOSTAT AND DOXORUBICIN COMBINATION ON PATIENT-DERIVED PRECLINICAL MODELS OF EPITHELIOID SARCOMA
Anna Maria Frezza
Favorite
(P 188) PRELIMINARY ASSESSMENT OF CIRCULATING INFLAMMATORY CYTOKINES IN EPITHELIOID HEMANGIOENDOTHELIOMA (EHE) PATIENTS AND IN AN EHE PATIENT-DERIVED XENOGRAFT BEFORE AND AFTER DOXORUBICIN AND SIROLIMUS
Anna Maria Frezza
Favorite
(P 204) PERCEPTIONS AND MANAGEMENT PRACTICES OF SARCOMA EXPERTS ABOUT SOFT TISSUE SARCOMA PATIENTS WITH ISOLATED LUNG METASTASES ACROSS EUROPE
Anna Maria Frezza
Favorite
Fridley, Brooke

Moffitt Cancer Center and Research Institute
(P 177) GENOMIC LANDSCAPE OF RARE EWSR1 FUSIONS
Brooke Fridley
Favorite
(P 256) TUMOR MUTATIONAL BURDEN AND MICROSATELLITE INSTABILITY IN LEIOMYOSARCOMA
Brooke Fridley
Favorite
Friedman, Claire

Memorial Sloan Kettering Cancer Center
(P 134) PHASE II STUDY OF RUCAPARIB AND NIVOLUMAB IN PATIENTS WITH LEIOMYOSARCOMA
Claire Friedman
Favorite
Fröhling, Stefan

Division of Translational Medical Oncology, National Center for Tumor Diseases (NCT) Heidelberg and German Cancer Research Center (DKFZ)
(P 176) FIBROBLAST ACTIVATION PROTEIN ALPHA AS THERANOSTIC TARGET IN SARCOMA
Stefan Fröhling
Favorite
(P 231) COMPREHENSIVE MOLECULAR PROFILING OF FOLLICULAR DENDRITIC CELL SARCOMA
Stefan Fröhling
Favorite
Frutos-Bernal, MDolores

“La Arrixaca” Clinical University Hospital
(P 055) PROGNOSTIC VALUE AND USEFULNESS OF HAEMATOLOGICAL BIOMARKERS IN LIPOSARCOMAS.
MDolores Frutos-Bernal
Favorite
(P 078) GASTROINTESTINAL STROMAL TUMOURS (GIST) AND RISK OF SECOND NEOPLASMS. INCIDENCE RATE ANALYSIS
MDolores Frutos-Bernal
Favorite
(P 219) PROGNOSTIC VALUE OF HEMATOLOGICAL MARKERS IN LEIOMYOSARCOMA
MDolores Frutos-Bernal
Favorite
(P 281) CUTANEOUS SARCOMA: CASE SERIES DESCRIPTION AND ANALYSIS OF FACTORS RELATED TO AN UNFAVORABLE EVOLUTION
MDolores Frutos-Bernal
Favorite
Fuchs, Bruno

Swiss Sarcoma Network
(P 072) ESTABLISHING A SARCOMA REFERENCE SCORE FOR EQ-5D
Bruno Fuchs
Favorite
Fuentes-Mateos, Raquel

Department of Medical Oncology, Ramón y Cajal University Hospital
(P 157) MOLECULAR SCREENING OF ADVANCED SARCOMAS THROUGH NEXT-GENERATION SEQUENCING IN A TERTIARY UNIVERSITY HOSPITAL
Raquel Fuentes-Mateos
Favorite
Fujii, Hiromasa

Nara Medical University
(P 181) MITOCHONDRIAL TRANSFER FROM MESENCHYMAL STEM CELSS MEDIATED BY HMGB1 COULD BE INVOLVED IN DRUG RESISTANCE IN OSTEOSARCOMA CELLS.
Hiromasa Fujii
Favorite
Fujiwara, Toshifumi

Kyushu University Department of Orthopaedic Surgery
(P 125) EFFECTIVENESS OF PERIPHERAL BLOOD IMMUNE-RELATED MARKERS IN SELECTING NOVEL THERAPEUTIC AGENTS FOR ADVANCED SOFT TISSUE SARCOMA
Toshifumi Fujiwara
Favorite
Fujiwara, Yasuhiro

Department of Medical Oncology, National Cancer Center Hospital
(P 147) ANALYSIS OF INFLAMMATORY BIOMARKERS AS PREDICTORS OF TREATMENT EFFICACY IN SOFT TISSUE SARCOMA TREATED WITH TRABECTEDIN
Yasuhiro Fujiwara
Favorite
Fuller, Robert

Gold Coast University Hospital
(P 299) PULMONARY METASTASECTOMY OF OSTEOSARCOMA VIA PNEUMONECTOMY AND MEDIAN STERNOTOMY WITH COMPLETE INTRATHORACIC LIVER MIGRATION: A CASE REPORT
Robert Fuller
Favorite
Fung, Kin Fen Kevin
(P 257) SELECTIVE INTRA-ARTERIAL DOXORUBICIN-ELUTING EMBOLIZATION FOR DESMOID FIBROMATOSIS: A COMBINED PROSPECTIVE AND RETROSPECTIVE STUDY
Kin Fen Kevin Fung
Favorite
Furman, Lauren

UT Southwestern Medical Center
(P 035) RISK FACTORS FOR BONY METASTASES IN PEDIATRIC OSTEOSARCOMA PATIENTS
Lauren Furman
Favorite